Tags

Type your tag names separated by a space and hit enter

Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
Postgrad Med J. 2007 Jun; 83(980):384-8.PM

Abstract

Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa-induced dyskinesias (LID). The underlying mechanisms for LID are unclear though recent studies indicate the importance of pulsatile stimulation of striatal postsynaptic receptors in their pathogenesis. The non-human primates with MPTP-induced parkinsonism serve as a useful model to study dyskinesia. Once established, LID are difficult to treat and therefore efforts should be made to prevent them. The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson's disease, amantadine, atypical neuroleptics, and neurosurgery. LID can adversely affect the quality of life and increase the cost of healthcare.

Authors+Show Affiliations

Department of Integrated Medicine, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. bhanvi@hotmail.comNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17551069

Citation

Thanvi, Bhomraj, et al. "Levodopa-induced Dyskinesia in Parkinson's Disease: Clinical Features, Pathogenesis, Prevention and Treatment." Postgraduate Medical Journal, vol. 83, no. 980, 2007, pp. 384-8.
Thanvi B, Lo N, Robinson T. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgrad Med J. 2007;83(980):384-8.
Thanvi, B., Lo, N., & Robinson, T. (2007). Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. Postgraduate Medical Journal, 83(980), 384-8.
Thanvi B, Lo N, Robinson T. Levodopa-induced Dyskinesia in Parkinson's Disease: Clinical Features, Pathogenesis, Prevention and Treatment. Postgrad Med J. 2007;83(980):384-8. PubMed PMID: 17551069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment. AU - Thanvi,Bhomraj, AU - Lo,Nelson, AU - Robinson,Tom, PY - 2007/6/7/pubmed PY - 2007/9/27/medline PY - 2007/6/7/entrez SP - 384 EP - 8 JF - Postgraduate medical journal JO - Postgrad Med J VL - 83 IS - 980 N2 - Levodopa is the most effective drug for treating Parkinson's disease. However, long-term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa-induced dyskinesias (LID). The underlying mechanisms for LID are unclear though recent studies indicate the importance of pulsatile stimulation of striatal postsynaptic receptors in their pathogenesis. The non-human primates with MPTP-induced parkinsonism serve as a useful model to study dyskinesia. Once established, LID are difficult to treat and therefore efforts should be made to prevent them. The therapeutic and preventative strategies for LID include using a lower dosage of levodopa, employing dopamine agonists as initial therapy in Parkinson's disease, amantadine, atypical neuroleptics, and neurosurgery. LID can adversely affect the quality of life and increase the cost of healthcare. SN - 1469-0756 UR - https://www.unboundmedicine.com/medline/citation/17551069/Levodopa_induced_dyskinesia_in_Parkinson's_disease:_clinical_features_pathogenesis_prevention_and_treatment_ DB - PRIME DP - Unbound Medicine ER -